Nothing Special   »   [go: up one dir, main page]

GB201712101D0 - nOMV-ANTIGEN CONJUGATES AND USE THEREOF - Google Patents

nOMV-ANTIGEN CONJUGATES AND USE THEREOF

Info

Publication number
GB201712101D0
GB201712101D0 GBGB1712101.3A GB201712101A GB201712101D0 GB 201712101 D0 GB201712101 D0 GB 201712101D0 GB 201712101 A GB201712101 A GB 201712101A GB 201712101 D0 GB201712101 D0 GB 201712101D0
Authority
GB
United Kingdom
Prior art keywords
nomv
antigen conjugates
conjugates
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1712101.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1712101.3A priority Critical patent/GB201712101D0/en
Publication of GB201712101D0 publication Critical patent/GB201712101D0/en
Priority to EP17816489.3A priority patent/EP3544637B1/en
Priority to HUE17816489A priority patent/HUE052751T2/en
Priority to BR112019010625A priority patent/BR112019010625A2/en
Priority to SI201730587T priority patent/SI3544637T1/en
Priority to JP2019527842A priority patent/JP7165468B2/en
Priority to PT178164893T priority patent/PT3544637T/en
Priority to LTEP17816489.3T priority patent/LT3544637T/en
Priority to BE2017/5856A priority patent/BE1025443B1/en
Priority to US16/462,630 priority patent/US20230137914A1/en
Priority to CN201780084566.9A priority patent/CN110248681A/en
Priority to EP20206493.7A priority patent/EP3799883A1/en
Priority to CA3044572A priority patent/CA3044572A1/en
Priority to PL17816489T priority patent/PL3544637T3/en
Priority to DK17816489.3T priority patent/DK3544637T3/en
Priority to ES17816489T priority patent/ES2847947T3/en
Priority to PCT/EP2017/080151 priority patent/WO2018096013A1/en
Priority to MX2019006105A priority patent/MX2019006105A/en
Priority to CY20211100044T priority patent/CY1123814T1/en
Priority to HRP20210121TT priority patent/HRP20210121T1/en
Priority to JP2022168070A priority patent/JP2023011688A/en
Ceased legal-status Critical Current

Links

GBGB1712101.3A 2016-11-25 2017-07-27 nOMV-ANTIGEN CONJUGATES AND USE THEREOF Ceased GB201712101D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB1712101.3A GB201712101D0 (en) 2017-07-27 2017-07-27 nOMV-ANTIGEN CONJUGATES AND USE THEREOF
MX2019006105A MX2019006105A (en) 2016-11-25 2017-11-23 nOMV-ANTIGEN CONJUGATES AND USE THEREOF.
CN201780084566.9A CN110248681A (en) 2016-11-25 2017-11-23 NOMV- antigen conjugate and application thereof
CA3044572A CA3044572A1 (en) 2016-11-25 2017-11-23 Nomv-antigen conjugates and use thereof
BR112019010625A BR112019010625A2 (en) 2016-11-25 2017-11-23 immunogenic conjugate, process for preparing the immunogenic conjugate, nomv-intermediate ligand, uses of the same and nomv, immunogenic composition, and vaccine.
SI201730587T SI3544637T1 (en) 2016-11-25 2017-11-23 Native omv-antigen conjugates and use thereof
JP2019527842A JP7165468B2 (en) 2016-11-25 2017-11-23 nOMV-antigen conjugates and uses thereof
PT178164893T PT3544637T (en) 2016-11-25 2017-11-23 Nomv-antigen conjugates and use thereof
LTEP17816489.3T LT3544637T (en) 2016-11-25 2017-11-23 Native omv-antigen conjugates and use thereof
BE2017/5856A BE1025443B1 (en) 2016-11-25 2017-11-23 NOMV-ANTIGEN CONJUGATES AND THEIR USE
US16/462,630 US20230137914A1 (en) 2016-11-25 2017-11-23 nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF
EP17816489.3A EP3544637B1 (en) 2016-11-25 2017-11-23 Native omv-antigen conjugates and use thereof
EP20206493.7A EP3799883A1 (en) 2016-11-25 2017-11-23 Nomv-antigen conjugated compounds and use thereof
HUE17816489A HUE052751T2 (en) 2016-11-25 2017-11-23 Native omv-antigen conjugates and use thereof
PL17816489T PL3544637T3 (en) 2016-11-25 2017-11-23 Native omv-antigen conjugates and use thereof
DK17816489.3T DK3544637T3 (en) 2016-11-25 2017-11-23 NATIVE OMV ANTIGEN CONJUGATES AND THEIR USE
ES17816489T ES2847947T3 (en) 2016-11-25 2017-11-23 Native VMEn-antigen conjugates and their use
PCT/EP2017/080151 WO2018096013A1 (en) 2016-11-25 2017-11-23 nOMV-ANTIGEN CONJUGATES AND USE THEREOF
CY20211100044T CY1123814T1 (en) 2016-11-25 2021-01-20 nOMV-ANTIGEN CONJUGATES AND THEIR USE
HRP20210121TT HRP20210121T1 (en) 2016-11-25 2021-01-22 Native omv-antigen conjugates and use thereof
JP2022168070A JP2023011688A (en) 2016-11-25 2022-10-20 nOMV-ANTIGEN CONJUGATES AND USE THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1712101.3A GB201712101D0 (en) 2017-07-27 2017-07-27 nOMV-ANTIGEN CONJUGATES AND USE THEREOF

Publications (1)

Publication Number Publication Date
GB201712101D0 true GB201712101D0 (en) 2017-09-13

Family

ID=59779005

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1712101.3A Ceased GB201712101D0 (en) 2016-11-25 2017-07-27 nOMV-ANTIGEN CONJUGATES AND USE THEREOF

Country Status (1)

Country Link
GB (1) GB201712101D0 (en)

Similar Documents

Publication Publication Date Title
ZA202003833B (en) Conjugates and preparation and use thereof
IL258248A (en) Affinity-oligonucleotide conjugates and uses thereof
IL268206A (en) Bcma-targeting antibody and use thereof
SI3592393T1 (en) Releasable conjugates
IL272524A (en) Clec9a binding agents and use thereof
IL293377B1 (en) Hsd17b13 variants and uses thereof
IL260323A (en) Antibodies and conjugates thereof
IL248961A0 (en) Auristatin derivatives and conjugates thereof
IL265471A (en) Affinity-oligonucleotide conjugates and uses thereof
IL264813B (en) 2-oxo-imidazopyridines and their use
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
PT3544637T (en) Nomv-antigen conjugates and use thereof
IL258759A (en) Anti-cd3-folate conjugates and their uses
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
SG11202003585VA (en) Anti-vista antibody and use thereof
IL269836B (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
ZA201906248B (en) Anti-ceacam1 antibody and use thereof
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
GB201615725D0 (en) Novel cytotoxic agents and conjugates thereof
IL275211A (en) Fast and partition-resilient blockchains
IL269843B (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
GB201818562D0 (en) Pyrrolobenzodiazephones and conjugates thereof
GB201712101D0 (en) nOMV-ANTIGEN CONJUGATES AND USE THEREOF
GB201712096D0 (en) Immunogenic conjugates and use thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)